Preliminary report on the use of danazol in the treatment of endometrial adenomatous hyperplasia

article OA: bronze CC0 ⤵ 8 in-corpus citations
AI-generated summary by gemini-2.5-flash-lite, 2026-06-07

Danazol treatment for 3 months resulted in symptom resolution and regression of adenomatous hyperplasia in five patients, suggesting its potential for treating this condition.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Since the authors recently reported that danazol inhibits the growth of human endometrial cancer cells in vitro, a clinical trial was initiated to examine whether danazol can regress adenomatous hyperplasia, a precursor of endometrial adenocarcinoma. Danazol was used for 3 months in the treatment of five patients with a history of hypermenorrhea and irregular uterine bleeding. Within a 9-month follow-up period, all patients were symptom-free, and none of the specimens obtained by endometrial biopsy showed the presence of adenomatous hyperplasia. These findings suggest that danazol has a potential application in the treatment of patients with endometrial adenomatous hyperplasia. A possible mechanism of action of the compound in adenomatous hyperplasia is also discussed.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (8)

Cited by (8)

Source provenance

openalex
last seen: 2026-05-11T05:56:47.744056+00:00
License: CC0 · commercial use OK